מדינה: ארצות הברית
שפה: אנגלית
מקור: NLM (National Library of Medicine)
LETROZOLE (UNII: 7LKK855W8I) (LETROZOLE - UNII:7LKK855W8I)
Bryant Ranch Prepack
ORAL
PRESCRIPTION DRUG
Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months [see Clinical Studies ( 14.2, 14.3)] . Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy
Letrozole Tablets, USP 2.5 mg tablets – yellow round, biconvex, film coated tablets imprinted with 'LT' on one side and plain on other side. NDC: 63629-7819-4: 40 Tablets in a BOTTLE NDC: 63629-7819-1: 30 Tablets in a BOTTLE NDC: 63629-7819-2: 10 Tablets in a BOTTLE NDC: 63629-7819-3: 90 Tablets in a BOTTLE Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504
Abbreviated New Drug Application
LETROZOLE- LETROZOLE TABLET, FILM COATED BRYANT RANCH PREPACK ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE LETROZOLE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR LETROZOLE TABLETS. LETROZOLE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1997 INDICATIONS AND USAGE Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3) DOSAGE AND ADMINISTRATION Letrozole tablets are taken orally without regard to meals ( 2): Recommended dose: 2.5.mg once daily ( 2.1) Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day ( 2.5, 5.3) DOSAGE FORMS AND STRENGTHS 2.5 mg tablets ( 3) CONTRAINDICATIONS Pregnancy ( 4) Known hypersensitivity to the active substance, or to any of the excipients ( 4) WARNINGS AND PRECAUTIONS Decreases in bone mineral density may occur. Consider bone mineral density monitoring ( 5.1) Increases in total cholesterol may occur. Consider cholesterol monitoring. ( 5.2) Fatigue, dizziness and somnolence may occur. Exercise caution when operating machinery ( 5.4) Embryo-Fetal toxicity: Can cause fetal harm when administered to pregnant women. Obtain a pregnancy test in females of reproductive potential. Advise females of reproductive potential to use effective contraception ( 5.6, 8.1, 8.3) ADVERSE REACTIONS The most common adverse reactions (greater than 20%) were hot flashes, arthralgia; flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, sweating increased, bone pain and musculoskeletal ( 6). TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT ACCORD HEALTHCARE INC. AT 1-866-941- 7875 OR FDA AT 1-800-FDA-10 קרא את המסמך השלם